{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:30:38Z","timestamp":1777951838721,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2026,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n Diabetic neuropathy, the most common long\u2010term complication of diabetes, frequently presents as painful diabetic peripheral neuropathy (pDPN), significantly impairing patients' quality of life. Pregabalin is an established treatment for pDPN, but optimal dosing and the influence of glycemic control on efficacy remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n To evaluate (1) the efficacy of different pregabalin doses for pDPN, and (2) the impact of baseline glycemic control, measured by glycosylated hemoglobin levels (HbA1c), on pregabalin's efficacy in reducing pain score.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Data from three randomized, double\u2010blind, placebo\u2010controlled trials involving 729 pDPN patients were pooled. Of these, 477 received pregabalin (75, 150, 300, or 600\u2009mg\/day) and 252 received placebo over 5\u20138\u2009weeks. Pain scores were recorded at baseline, weekly, and at the endpoint. Patients were stratified by HbA1c: \u22648% (\n n<\/jats:italic>\n \u2009=\u2009377) and >8% (\n n<\/jats:italic>\n \u2009=\u2009346). Analysis of covariance (\n ancova)<\/jats:sc>\n assessed changes in endpoint pain scores; MMRM evaluated changes over time.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Pregabalin 300\u2009mg\/day and 600\u2009mg\/day significantly reduced mean pain scores versus placebo (\n P<\/jats:italic>\n \u2009<\u20090.0001), while 75\u2009mg\/day and 150\u2009mg\/day did not. In HbA1c subgroups, pregabalin maintained efficacy at 300\u2009mg\/day and 600\u2009mg\/day regardless of baseline glycemic control. Among patients with HbA1c \u22648%, pain reductions versus placebo were \u22121.69 and \u22121.71 for the 300\u2009mg\/day and 600\u2009mg\/day groups, respectively (\n P<\/jats:italic>\n \u2009<\u20090.0001). In patients with HbA1c >8%, reductions were \u22121.04 and \u22121.09 (\n P<\/jats:italic>\n \u2009\u2264\u20090.001), demonstrating efficacy independent of glycemic control.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Pregabalin at 300 and 600\u2009mg\/day provides significant pain relief in pDPN, regardless of HbA1c levels, supporting dose optimization to achieve maximal benefit.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jdi.70288","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:50:15Z","timestamp":1773845415000},"page":"827-834","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pregabalin efficacy in painful diabetic peripheral neuropathy: A focused analysis of optimal dosing and the relationship of baseline glycemic control"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4262-1091","authenticated-orcid":false,"given":"Ashish","family":"Bajaj","sequence":"first","affiliation":[{"name":"Global Medical Affairs, Viatris Inc. Bengaluru Karnataka India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-2662","authenticated-orcid":false,"given":"Gordon","family":"Sloan","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine University of Sheffield Sheffield South Yorkshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Walker","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Viatris Inc. Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Biesheuvel","sequence":"additional","affiliation":[{"name":"Biometrics, Data Management & Programming Viatris Inc. Amstelveen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar Suresh","family":"Kumbhar","sequence":"additional","affiliation":[{"name":"Biometrics, Viatris Inc. Bengaluru Karnataka India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Lyndon","sequence":"additional","affiliation":[{"name":"GL Healthcare Consultancy Ltd. Dorking UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Tesfaye","sequence":"additional","affiliation":[{"name":"Diabetes Sheffield Teaching Hospitals Sheffield Yorkshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"IDF Diabetes Atlas Global Diabetes Data and Statistics.Diabetes Atlas 2025.https:\/\/diabetesatlas.org\/."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00496-z"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114522135"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S370050"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01100-2"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182166ebe"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00068-7"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.032"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70065-0"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0664-6"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.4.956"},{"key":"e_1_2_12_13_1","first-page":"230","article-title":"Painful diabetic neuropathy","volume":"14","author":"Sundara Rajan R","year":"2014","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.12.007"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.001"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0939"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003075"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001952"},{"key":"e_1_2_12_20_1","first-page":"CD007076","article-title":"Pregabalin for acute and chronic pain in adults","volume":"3","author":"Moore RA","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000492"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2042"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013038"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01472-6"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/db2022-01"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1857992"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.70288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:08:23Z","timestamp":1777892903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.70288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdi.70288"],"URL":"https:\/\/doi.org\/10.1111\/jdi.70288","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"2025-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}